Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin vs Injection Augmentation for Essential Voice Tremor
NCT02711995Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Polymer-based Nanoparticles, Hydrogel Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of RenuGel in essential tremor (ET) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Vocal Tremor Scoring System at 30 days. Started Dec 2015; status: completed.
02
Drugs
RenuGel
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT02711995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711995.